Forus raises $150M at a $3B valuation, four months after hitting $1B

Why it matters

Forus is testing whether a healthcare AI company can give its provider product away, use venture capital to capture distribution and monetize the resulting network through drugmakers. The $3 billion valuation prices that model for rapid growth before its customer concentration and contract economics are visible publicly.

Sahir Jaggi (@sahirjaggi) has raised $150 million for Forus at a $3 billion valuation, tripling Forus's reported value roughly four months after its previous financing. Bloomberg reported Tuesday that Bain Capital Ventures led the Series C, with Accel, Thrive Capital, General Catalyst, Redpoint Ventures, BoxGroup and Pear VC participating.

The round gives Jaggi, a Columbia-trained biomedical engineer who spent years working on product and patient experience at Oscar Health, another large pool of capital for a strategy he settled on before Forus had revenue: give the core software to doctors and patients for free, build the largest medication-access network possible, and charge biopharmaceutical companies that need help getting drugs to market and into patients' hands.

Jaggi arrived at that model after abandoning an earlier startup idea. In a Columbia in Tech interview, he recalled preparing to leave Oscar and begin fundraising before an investor told him the idea was not good enough. Jaggi remained at Oscar for about another year, using the time to research healthcare problems. Large language models were beginning to show they could process fragmented information and handle repetitive, multistep work. At the same time, the scramble to obtain GLP-1 drugs was making the gap between receiving a prescription and starting treatment unusually visible.

He founded Tandem in early 2023. Forus adopted its current name in May, when Forus said it had raised more than $160 million across its seed, Series A and Series B financings. Jaggi later identified the Series B as a $125 million round. Adding the latest financing brings Forus's disclosed capital to at least $310 million in less than four years.

A free product with a paid network behind it

Forus takes over the administrative work that begins after a clinician chooses a medication. Its software verifies insurance benefits, prepares prior authorizations and appeals, enrolls patients in financial-assistance programs, routes prescriptions to pharmacies and tracks whether the medicine reaches the patient.

Forus says its system works across drugs, insurers and pharmacies and remains free for providers and patients. That removes a purchasing decision from medical practices, many of which lack the staff or budget to install another paid healthcare application. It also shifts the commercial burden to drugmakers, which pay Forus through medication-access and launch programs.

The decision delayed revenue. Jaggi told General Catalyst that Forus made no money from its core customers during its first two years. He also said Forus turned down opportunities worth millions, and in some cases tens of millions, that did not fit its strategy. His description of the provider pricing plan was more concise in the Columbia interview: "It's free forever."

Forus says its platform is used by thousands of providers in all 50 states and reaches patients in roughly 80% of US ZIP codes. General Catalyst says tens of thousands of patients use the platform weekly; those figures have not been independently verified.

The moat Jaggi is trying to buy

Jaggi's underlying bet is that the AI models used to process forms, records and insurer rules will become cheaper and easier for competitors to obtain. Forus is spending venture capital to establish distribution before that happens.

Each prescription gives Forus another record of how a particular drug, diagnosis, insurer and pharmacy combination moved through the system. Forus can reuse those outcomes when handling later cases and offer drugmakers a view into where prescriptions stall, why patients abandon treatment and which administrative requirements slow a launch.

Accel argued when it invested in the Series B that the growing prescription network, rather than access to any particular model, could become the durable asset. The additional $150 million gives Forus the option to subsidize provider adoption and expand its prescription-processing capacity while pursuing that strategy.

The field is already crowded. Infinitus uses voice agents for benefits verification, prior-authorization follow-up and calls between providers, pharmacies and payers. Humata Health focuses on automating prior authorization for medical procedures and specialty drugs. Forus is pursuing a wider workflow, carrying a prescription from the doctor's decision through insurance, affordability and pharmacy fulfillment.

Forus's broader remit carries a larger product and operational burden. The Series C gives Forus the option to add capacity as prescription volume grows.

What the $3 billion mark assumes

Forus told Forbes in May that annualized revenue had risen above $50 million, nearly five times its pace at the end of 2025. Annualized revenue is a run-rate measure, and the figure was supplied by Forus rather than independently audited. No newer revenue figure accompanied the Series C report.

The $3 billion valuation places a substantial premium on continued provider growth and Forus's ability to turn that usage into durable biopharma contracts. Public disclosures do not break out revenue concentration, contract duration or the economics of individual drug-launch programs. Those details matter because providers and patients contribute activity to the network without contributing revenue.

The investor list shows that existing backers remain willing to finance that gap. Bain Capital Ventures has backed Forus since its early financing and led the new round. Accel, Thrive Capital, General Catalyst, Redpoint Ventures, BoxGroup and Pear VC all returned.

For Jaggi, the capital preserves the original trade: absorb the cost and complexity for doctors, then build a commercial business around the resulting network. Investors have now assigned that strategy a $3 billion price, only months after valuing it at $1 billion. Forus still has to prove the network can support that pace once the easy part of giving software away gives way to the harder work of making the economics hold.